Author

Gijs van de Wetering

Observed names: G Wetering, G van de Wetering, G. Van de Wetering, G. van de Wetering, Gijs Van De Wetering, Gijs Van de Wetering, van de Wetering, Gijs

Observed institutions: Radboud University Nijmegen, Radboud University Medical Center, AbbVie (United States), Pharmerit (Netherlands), Dana-Farber Cancer Institute, University of Twente

ORCID: 0009-0001-6498-2950

Observed ORCID: 0009-0001-6498-2950

OpenAlex ID: A5036545592

A Systematic and Critical Review of the Evolving Methods and Applications of Value of Information in Academia and Practice

2012 · Lotte Steuten, Gijs van de Wetering, et al. · PharmacoEconomics · 84

The CareWell-primary care program: design of a cluster controlled trial and process evaluation of a complex intervention targeting community-dwelling frail elderly

2012 · Franca GH Ruikes, Antoinette RM Meys, et al. · BMC Family Practice · 27

PDF

Time to incorporate time in cost-effectiveness analysis

2012 · Gijs van de Wetering, Willem H. Woertman, et al. · The European Journal of Health Economics · 23

PDF

Cost-effectiveness of a 12-month fixed-duration venetoclax treatment in combination with obinutuzumab in first-line, unfit chronic lymphocytic leukemia in the United States

2021 · Anuja Chatterjee, Sheila Shapouri, et al. · Journal of Managed Care & Specialty Pharmacy · 21

PDF

Cost-effectiveness analysis of anti–IL-5 therapies of severe eosinophilic asthma in Spain

2021 · Francisco Javier González-Barcala, Xavier Muñoz-Gall, et al. · Journal of Medical Economics · 17

PDF

A model to correct for short‐run inefficiencies in economic evaluations in healthcare

2011 · Gijs Van de Wetering, Willem H. Woertman, et al. · Health Economics · 15

Biologic treatment sequences for plaque psoriasis: a cost-utility analysis based on 10 years of Dutch real-world evidence from BioCAPTURE

2017 · S.L. Klijn, J.M.P.A. van den Reek, et al. · British Journal of Dermatology · 13

A Probabilistic Cost-Effectiveness Analysis of Venetoclax and Obinutuzumab as a First-Line Therapy in Chronic Lymphocytic Leukemia in Canada

2022 · Anuja Chatterjee, Gijs van de Wetering, et al. · PharmacoEconomics - Open · 12

PDF

Cost-Effectiveness of a 12-Month Fixed Duration of Venetoclax in Combination with Obinutuzumab in First-Line Chronic Lymphocytic Leukemia in the United States

2019 · Matthew S. Davids, Anuja Chatterjee, et al. · Blood · 11

Quantifying short run cost-effectiveness during a gradual implementation process

2012 · Gijs van de Wetering, Willem H. Woertman, et al. · The European Journal of Health Economics · 11

Early Bayesian modeling of a potassium lab-on-a-chip for monitoring of heart failure patients at increased risk of hyperkalaemia

2012 · Gijs van de Wetering, Lotte M.G. Steuten, et al. · Technological Forecasting and Social Change · 9

Cost-Effectiveness on a Local Level: Whether and When to Adopt a New Technology

2013 · Willem H. Woertman, Gijs Van De Wetering, et al. · Medical Decision Making · 7

Cost-effectiveness of nivolumab and ipilimumab versus pembrolizumab and axitinib in advanced renal cell carcinoma with intermediate or poor prognostic risk: a Brazilian private healthcare system perspective

2023 · Nishit Dhanji, Tassia Cristina Decimoni, et al. · Journal of Medical Economics · 6

PDF

Panobinostat Plus Bortezomib Versus Lenalidomide in Patients with Relapsed and/or Refractory Multiple Myeloma: A Matching-Adjusted Indirect Treatment Comparison of Survival Outcomes using Patient-level Data

2016 · Istvan Majer, Gijs van de Wetering, et al. · Applied Health Economics and Health Policy · 6

Understanding and Anticipating Lag-time Bias in Cost-effectiveness Studies: the Role of Time in Cost-effectiveness Analysis

2014 · Gijs van de Wetering, Marcel Olde Rikkert, et al. · International Journal of Technology Assessment in Health Care · 6

Modification of treatment-sequence model with a customizable number of treatments to better reflect contemporary and future clinical practice in moderate to severe psoriasis

2022 · Gijs van de Wetering, Tim Ignacio, et al. · Journal of Medical Economics · 5

Cost-effectiveness of zanubrutinib versus ibrutinib in adult patients with Waldenström macroglobulinemia in the United States.

2021 · Jorge J. Castillo, Keri Yang, et al. · Journal of Clinical Oncology · 5

Mo4 Using Ahp Weights to Fill Missing Gaps in Markov Decision Models

2010 · L Steuten, M Hummel, et al. · Value in Health · 5

PDF

Long-Term Mortality and Morbidity Impact on Patients with Pulmonary Arterial Hypertension (PAH) If Access to Sotatercept Is Delayed: A Simulation Model

2025 · Adnan Alsumali, Vallerie McLaughlin, et al. · Advances in Therapy · 2

PDF

A cost-effectiveness analysis of deucravacitinib vs. apremilast in moderate-to-severe psoriasis patients in Japan

2025 · Gijs van de Wetering, Hyunchung Kim, et al. · Journal of Medical Economics · 2

Transforming PAH care in Italy: a clinical and economic evaluation of sotatercept add-on therapy

2025 · Martina Paoletti, Andrea Marcellusi, et al. · Journal of Medical Economics · 1

PDF

Cost-Effectiveness of a 12-Month Fixed Duration of Venetoclax in Combination with Obinutuzumab Versus Chemoimmunotherapy and Other Novel Combinations in First-Line Chronic Lymphocytic Leukemia in Canada

2020 · Anuja Chatterjee, Gijs Van de Wetering, et al. · Blood · 1

Pcn170 Cost-effectiveness of Nivolumab in Combination With Ipilimumab Compared to Sunitinib in the First-line Treatment of Advanced or Metastatic Intermediate- or Poor-risk Renal Cell Carcinoma in Italy

2019 · P. Di Rienzo, L. Zarrelli, et al. · Value in Health · 1

Pcn190 - Cost-effectiveness of Nivolumab + Ipilimumab in First-line Treatment of Advanced or Metastatic Renal Cell Carcinoma in the Netherlands

2018 · S. Klijn, G. Van de Wetering, et al. · Value in Health · 1

P57 The cost-consequence of fluticasone furoate/vilanterol 100/25 MCG in the uk using the results from the COPD salford lung study

2016 · MT Driessen, S Barnfather, et al. · Thorax · 1

PDF

Works count: 53

Citation count: 292

H-index: 10

I10-index: 10